Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated June 8, 2026, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries. The filing details transactions executed under a programme initiated on May 6, 2026, which is part of a broader 12-month repurchase plan starting February 4, 2026.
Key Financial Metrics
The filing focuses on capital allocation via share buybacks rather than operational financial performance metrics such as revenue or profit.
- Total Repurchase Programme Cap: Up to DKK 15 billion over 12 months (starting Feb 4, 2026).
- Specific Programme (May 6, 2026): Up to DKK 11,200,000,010.45 for B shares.
- Accumulated Repurchases (as of June 4, 2026): 18,759,179 B shares purchased since Feb 4, 2026.
- Total Value Repurchased (as of June 4, 2026): DKK 4,958,452,482.
- Average Purchase Price (since Feb 4, 2026): DKK 264.32 per B share.
- Treasury Shares Held: 35,944,480 B shares (0.8% of total share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Transactions
Between June 1, 2026, and June 4, 2026, the company executed four transactions under the specific programme initiated on May 6, 2026:
| Date | Shares Purchased | Avg. Price (DKK) | Transaction Value (DKK) |
|---|---|---|---|
| June 1, 2026 | 210,000 | 292.91 | 61,512,149 |
| June 2, 2026 | 210,000 | 280.05 | 58,810,689 |
| June 3, 2026 | 225,000 | 276.91 | 62,305,652 |
| June 4, 2026 | 225,000 | 278.01 | 62,553,306 |
| Accumulated (Programme) | 4,000,000 | - | 1,158,452,492 |
These transactions represent a continuation of the broader buyback strategy, with the average price fluctuating between DKK 276.91 and DKK 292.91 during this specific four-day window.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the DKK 15 billion limit during the 12-month period beginning February 4, 2026. The company aims to defeat serious chronic diseases through scientific breakthroughs and expanded access to medicines.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard execution of the share repurchase programme under EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Unusual Items: None reported in this filing.
Key Facts for Investor Verification
- Verify the remaining capacity under the DKK 15 billion total repurchase programme (approx. DKK 10.04 billion remaining as of June 4, 2026).
- Confirm the impact of the 0.8% treasury share holding on earnings per share (EPS) calculations in upcoming financial reports.
- Monitor the average purchase price trend relative to the market price of B shares to assess capital allocation efficiency.
- Check subsequent filings for updates on the total number of shares repurchased as the 12-month period progresses.